# A Study to Evaluate the Effectiveness and Safety of Tapentadol (CG5503) in the Treatment of Acute Pain From Bunionectomy Compared With Placebo

> **NCT01813890** · PHASE3 · COMPLETED · sponsor: **Janssen-Cilag International NV** · enrollment: 60 (actual)

## Conditions studied

- Hallux Valgus

## Interventions

- **DRUG:** Tapentadol IR 50 mg
- **DRUG:** Tapentadol IR 75 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01813890
- **Lead sponsor:** Janssen-Cilag International NV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-01
- **Primary completion:** 2014-01
- **Final completion:** 2014-01
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2015-01-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01813890

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01813890, "A Study to Evaluate the Effectiveness and Safety of Tapentadol (CG5503) in the Treatment of Acute Pain From Bunionectomy Compared With Placebo". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01813890. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*